Talath Sirajunisa, Gadad Andanappa K
Department of Medicinal Chemistry, College of Pharmacy, J. N. Medical College, Belgaum, Karnataka, India.
Arzneimittelforschung. 2006;56(11):744-52. doi: 10.1055/s-0031-1296785.
In search for potential prodrugs for anti-inflammatory drug candidates in the niflumate series, novel morpholinoalkyl ester prodrugs of niflumic acid (CAS 4394-00-7) 5a-b were prepared by esterification of appropriate morpholinylalkyl alcohols 3a-b with niflumic acid 4 in the presence of dicyclohexyl carbodiimide (DCC) and catalyst dimethylamino pyridine (DMAP) at 0-5 degrees C. The structures were confirmed by elemental and spectral data (UV, IR, 1H-NMR, 13C-NMR, and EI-MS). The ester prodrugs 5a-b showed better solubility than the parent drug niflumic acid 4 in simulated gastric fluid (SGF) and phosphate buffer (pH 7.4). The in vitro hydrolysis studies were conducted at pH 1.3 (SGF), phosphate buffer (pH 7.4) and in human plasma diluted with phosphate buffer (pH 7.4) at 37+/-0.5 degrees C using HPLC with UV detection. The ester prodrugs 5a-b were quantitatively hydrolyzed to the parent drug niflumic acid 4 by enzymatic and/or chemical means. It is observed that an increase in the carbon chain length rendered the prodrugs 5a-b more stable in phosphate buffer (pH 7.4) than in pH 1.3 (SGF), but they were rapidly hydrolyzed in human plasma at 37+/-0.5 degrees C. They exhibited longer hydrolytic half-lives of 16.11-53.30 h in aqueous buffer solutions (pH 1.3 and 7.4) and 1.63-2.73 min in human plasma, respectively. The title compounds were evaluated in vivo for anti-inflammatory activity in carrageenan induced rat paw oedema model in rats at the doses 45, 90, 150 mg/kg b.w. The test compounds exhibited good anti-inflammatory activity (46.6-53.2 % at the dose of 150 mg/kg b. w.) with respect to niflumic acid (78.7 % at the dose of 90 mg/kg b.w.). The compounds were also screened for in vivo ulcerogenicity, it was observed that the prodrug 5b was significantly less irritating to gastric mucosa than compound 5a and the parent drug niflumic acid 4 following single and chronic oral administration in rats.
为了寻找尼氟灭酸系列抗炎候选药物的潜在前体药物,在二环己基碳二亚胺(DCC)和催化剂4-二甲氨基吡啶(DMAP)存在下,于0 - 5℃,使适当的吗啉基烷基醇3a - b与尼氟灭酸4酯化,制备了新型的尼氟灭酸(CAS 4394 - 00 - 7)吗啉代烷基酯前体药物5a - b。通过元素分析和光谱数据(紫外、红外、1H - NMR、13C - NMR和电子轰击质谱)确定了结构。酯前体药物5a - b在模拟胃液(SGF)和磷酸盐缓冲液(pH 7.4)中的溶解度比母体药物尼氟灭酸4更好。在37±0.5℃,使用带紫外检测的高效液相色谱法,在pH 1.3(SGF)、磷酸盐缓冲液(pH 7.4)以及用磷酸盐缓冲液(pH 7.4)稀释的人血浆中进行体外水解研究。酯前体药物5a - b通过酶促和/或化学方法定量水解为母体药物尼氟灭酸4。观察到碳链长度增加使前体药物5a - b在磷酸盐缓冲液(pH 7.4)中比在pH 1.3(SGF)中更稳定,但它们在37±0.5℃的人血浆中迅速水解。它们在水性缓冲溶液(pH 1.3和7.4)中的水解半衰期分别为16.11 - 53.30小时,在人血浆中的水解半衰期为1.63 - 2.73分钟。在角叉菜胶诱导的大鼠足肿胀模型中,以45、90、150 mg/kg体重的剂量对标题化合物进行体内抗炎活性评价。相对于尼氟灭酸(90 mg/kg体重剂量时为78.7%),受试化合物表现出良好的抗炎活性(150 mg/kg体重剂量时为46.6 - 53.2%)。还对化合物进行了体内致溃疡性筛选,观察到在大鼠单次和长期口服给药后,前体药物5b对胃黏膜的刺激性明显小于化合物5a和母体药物尼氟灭酸4。